<SEC-DOCUMENT>0001171843-23-006749.txt : 20231106
<SEC-HEADER>0001171843-23-006749.hdr.sgml : 20231106
<ACCEPTANCE-DATETIME>20231106070011
ACCESSION NUMBER:		0001171843-23-006749
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20231102
FILED AS OF DATE:		20231106
DATE AS OF CHANGE:		20231106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		231378073

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_110223.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549 </B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>FORM 6-K </B></P>

<P STYLE="margin: 0pt 0; font-size: 18pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Date of report: November 02, 2023 </B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Commission File Number: 001-38844 </B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 24pt; text-align: center; margin: 0pt 0"><B>GENFIT S.A. </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Translation of registrant&rsquo;s name into English) </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>59120 Loos, France</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Address of principal executive office) </B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&#9746; Form 20-F &#9744; Form 40-F</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>EXHIBIT LIST</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-size: 10pt">Press Release dated November 02, 2023.</FONT></A></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: November 02, 2023</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="hdr.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-weight: bold; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt; color: rgb(0,84,120)">GENFIT to Present Update on Scientific
and Corporate Progress <FONT STYLE="letter-spacing: -0.4pt">at The Liver Meeting&reg; 2023</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.9pt"></TD><TD STYLE="width: 17.95pt"><FONT STYLE="font-family: Symbol"><B>&middot;</B></FONT></TD><TD STYLE="text-align: justify"><B>GENFIT
                                            to lead 3 key events on ACLF during <FONT STYLE="letter-spacing: -0.1pt">AASLD:</FONT></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.9pt"></TD><TD STYLE="width: 17.95pt"><B>o</B></TD><TD STYLE="text-align: left"><B>ACLF Day for Investors/Analysts on November
                                            11, <FONT STYLE="letter-spacing: -0.2pt">2023</FONT></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.9pt"></TD><TD STYLE="width: 17.95pt"><B>o</B></TD><TD STYLE="text-align: left"><B>Patient Advocacy Council meeting on November
                                            11, <FONT STYLE="letter-spacing: -0.2pt">2023</FONT></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.9pt"></TD><TD STYLE="width: 17.95pt"><B>o</B></TD><TD STYLE="text-align: left"><B>ACLF Investigator event on November 12,
                                            <FONT STYLE="letter-spacing: -0.2pt">2023</FONT></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol"><B>&middot;</B></FONT></TD><TD STYLE="text-align: justify; padding-right: 5.7pt"><FONT STYLE="letter-spacing: -0.4pt"><B>Detailed
                                            interim data from the ELATIVE&reg; Phase 3 results evaluating elafibranor in PBC to be presented
                                            by GENFIT&rsquo;s partner Ipsen, in a late breaking oral session on </B></FONT><B>November
                                            13, 2023</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.9pt"></TD><TD STYLE="width: 17.95pt"><FONT STYLE="font-family: Symbol"><B>&middot;</B></FONT></TD><TD STYLE="text-align: justify"><B>GENFIT
                                            to present new data on its NASH1 diagnostics <FONT STYLE="letter-spacing: -0.1pt">technology</FONT></B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Lille (France), Cambridge (Massachusetts, United
States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT)</B>, a late-stage biopharmaceutical company dedicated
<FONT STYLE="letter-spacing: -0.1pt">to improving the lives of patients with rare and severe liver diseases, today announced that it
will present an update on its scientific and corporate progress at The Liver Meeting<FONT STYLE="font-size: 10pt">&reg;</FONT> 2023 organized
</FONT><FONT STYLE="letter-spacing: -0.4pt">by the American Association for the Study of Liver Diseases (AASLD), which will take place
in Boston, </FONT><FONT STYLE="letter-spacing: -0.1pt">MA (USA) from November 10-14, 2023.</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><B>GENFIT to lead 3 key events on
Acute on Chronic Liver Failure (ACLF) during <FONT STYLE="letter-spacing: -0.1pt">AASLD</FONT></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.1pt">ACLF
</FONT><FONT STYLE="letter-spacing: -0.25pt">Day</FONT></P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">GENFIT will host an Investor/Analyst event on Saturday,
November 11, 2023 at 12.30pm ET in Boston with the participation of key stakeholders:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.8pt">Dr.
                                            Jennifer Lai (MD, MBA, FACP, Transplant hepatologist, University of California, San Francisco
                                            (UCSF), USA) will present the ACLF disease state, patient journey and unmet medical needs
                                            in ACLF</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.9pt">Robert
                                            Stolper, Managing Principal and Pierre-Antoine Andre, Vice President from IQVIA will present
                                            the ACLF market opportunity</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">____________________________</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.1pt"><SUP>1</SUP> At EASL Congress in
June 2023 it was announced that nonalcoholic steatohepatitis (NASH) would now be referred to as </FONT><FONT STYLE="letter-spacing: -0.2pt">Metabolic
dysfunction-associated steatohepatitis (MASH). Nonalcoholic fatty liver disease (NAFLD) will now be referred to </FONT><FONT STYLE="letter-spacing: -0.1pt">as
metabolic dysfunction-associated steatotic liver disease (MASLD). GENFIT is progressively transitioning its </FONT>documentation over
to this new nomenclature and both NASH and MASH terms may appear in our documents during this period.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 29px; width: 700px"></TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><IMG SRC="hdr.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><B><I>ACLF Investigator <FONT STYLE="letter-spacing: -0.2pt">Event</FONT></I></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.1pt">GENFIT will
host an ACLF Investigator event on Sunday, November 12, 2023 at 6.30pm ET at the </FONT>Hilton Boston Back Bay, Westminster. Participants
include study investigators, principal investigators and other healthcare professionals from the US, France, Germany and the UK.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Patient Advocacy
Council <FONT STYLE="letter-spacing: -0.1pt">Meeting</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.3pt">Two Patient
Advocacy Council sessions will be held on Saturday November 11, 2023. Topics on the </FONT><FONT STYLE="letter-spacing: -0.1pt">agenda
include developing a robust patient engagement plan with a specific focus on ACLF, and </FONT>further initiatives to facilitate patient
access to innovative medicine through clinical trials and <FONT STYLE="letter-spacing: -0.3pt">patient perspectives and insights. Participants
in this event include Dr. Jennifer Lai (MD, MBA, FACP) </FONT>and the Global Liver Institute.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><B>Interim data disclosure for the
ELATIVE&reg; Phase 3 trial evaluating elafibranor in <FONT STYLE="letter-spacing: -0.25pt">PBC</FONT></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.1pt">Ipsen will
present the full 52-week results from the ELATIVE&reg; Phase 3 trial evaluating elafibranor </FONT>in Primary Biliary Cholangitis (PBC)
in a late-breaking oral session (Abstract #484, Monday, November 13 at 4.45pm ET).</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Following the late-breaker presentation of the ELATIVE&reg;
Phase 3 interim results, Ipsen plans to host a conference call for analysts and investors on Tuesday November 14 at 4.00pm CET / <FONT STYLE="letter-spacing: -0.2pt">10.00am
ET. Joining the event will be Dr. Christopher Bowlus, Lena Valente Professor and Chief of </FONT>the Division of Gastroenterology and
Hepatology at the University of California Davis School of Medicine, presenter of the late-breaker session.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005278"><B>GENFIT&rsquo;s NASH diagnostics
technology <FONT STYLE="letter-spacing: -0.1pt">presentations</FONT></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #090909">GENFIT
will present new data on its NASH diagnostics technology, <FONT STYLE="letter-spacing: -0.1pt">including:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.6pt">Performances
                                            of NIS2+&trade; and other non-invasive tests for the detection of at-risk NASH along the
                                            BMI (Body Mass Index) spectrum (Poster #2089-A)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.85pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.3pt">The
                                            impact of BMI on NIS2+&trade; and established non-invasive tests for the evaluation of non-
                                            </FONT><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">alcoholic liver disease (15&rsquo;
                                            Oral Presentation #238, Pr. Sven Francque</FONT><FONT STYLE="letter-spacing: -0.1pt">)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt">The
                                            sequential use of FIB-4 and NIS2+&trade; for an accurate detection of non-cirrhotic at-risk
                                            NASH patients for enrollment in NASH clinical trials (Poster of Distinction #2100-A</FONT><FONT STYLE="letter-spacing: -0.1pt">)<SUP>2</SUP></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.75pt"><FONT STYLE="font-size: 10pt">NIS2-mice,
                                            an adaptation of the clinical NIS2+&trade; diagnostic test for the detection of NAS &ge;4
                                            &amp; F &ge;2 in GAN diet-induced obese and biopsy confirmed mouse model of NASH with <FONT STYLE="letter-spacing: -0.1pt">advanced
                                            fibrosis (Poster #2082-A, in collaboration with Gubra</FONT></FONT><FONT STYLE="letter-spacing: -0.1pt">)</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">______________________________</P>

<P STYLE="font-size: 10pt; text-indent: -0.05pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.2pt"><SUP>2</SUP>
Abstract identified as &ldquo;Poster of Distinction.&rdquo; These are classified as being in the top 5% of scored poster abstracts and
</FONT>will receive special recognition in the Poster Hall.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 29px; width: 700px"></TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><IMG SRC="hdr.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #090909">LabCorp
Product <FONT STYLE="letter-spacing: -0.1pt">Theater</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">LabCorp, GENFIT&rsquo;s commercial partner for its
diagnostics technology, will also host a Product Theater, highlighting recent data for NIS4<FONT STYLE="font-size: 10pt">&reg;</FONT>
and NIS2+<FONT STYLE="font-size: 10pt">&trade; </FONT>technology and their use in patient <FONT STYLE="letter-spacing: -0.1pt">management,
as well as in clinical trials. A 30-minute presentation will be held with Dr. Stephen Harrison speaking on Monday, November 13 from 1:30-2:00
PM ET at the Plaza Level exhibit hall </FONT>(Product Theater #2).</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.25pt"><B>END</B></FONT></P>

<P STYLE="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #005478"><B>ABOUT <FONT STYLE="letter-spacing: -0.1pt">AASLD</FONT></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">AASLD is the leading organization of scientists
and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment
<FONT STYLE="letter-spacing: -0.2pt">options for millions of liver disease patients. They advance the science and practice of hepatology
through educational conferences, training programs, professional publications, and partnerships </FONT>with government agencies and sister
societies.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #005478"><B>ABOUT <FONT STYLE="letter-spacing: -0.1pt">GENFIT</FONT></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.05pt; margin-top: 0pt; margin-bottom: 0pt">GENFIT is a late-stage biopharmaceutical
company dedicated to improving the lives of patients <FONT STYLE="letter-spacing: -0.2pt">with rare and life-threatening liver diseases
characterized by high unmet medical needs. GENFIT is </FONT>a pioneer in liver disease research and development with a rich history and
strong scientific <FONT STYLE="letter-spacing: -0.1pt">heritage spanning more than two decades. Today, GENFIT has a growing and diversified
pipeline with programs at various development stages. The Company&rsquo;s area of focus is Acute on Chronic </FONT><FONT STYLE="letter-spacing: -0.3pt">Liver
Failure (ACLF). Its ACLF franchise consists of five assets in development: VS-01, NTZ, SRT-015, </FONT>CLM-022 and VS-02-HE. These are
all based on differentiated mechanisms of action leveraging <FONT STYLE="letter-spacing: -0.1pt">complementary pathways. Other assets
target other life-threatening disease indications such as </FONT><FONT STYLE="letter-spacing: -0.3pt">cholangiocarcinoma (CCA) and Urea
Cycle Disorders (UCD)/Organic Acidemias (OA). GENFIT&rsquo;s track </FONT>record in bringing early-stage assets with high potential to
late development and pre- commercialization stages is highlighted in the successful 52-week Phase 3 ELATIVE&reg; trial <FONT STYLE="letter-spacing: -0.1pt">evaluating
elafibranor in PBC. Beyond therapeutics, GENFIT&rsquo;s pipeline also includes a diagnostic </FONT><FONT STYLE="letter-spacing: -0.3pt">franchise
focused on MASH (previously known as NASH) and ammonia. GENFIT has facilities in Lille </FONT>and Paris (France), Zurich (Switzerland)
and Cambridge, MA (USA). GENFIT is a publicly traded <FONT STYLE="letter-spacing: -0.3pt">company listed on the Nasdaq Global Select
Market and on compartment B of Euronext&rsquo;s regulated </FONT>market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one
of GENFIT&rsquo;s largest shareholders and holds 8% of the company&rsquo;s share capital. For more information, visit <FONT STYLE="letter-spacing: -0.1pt">www.genfit.com</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 29px; width: 700px"></TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><IMG SRC="hdr.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><B>FORWARD LOOKING <FONT STYLE="letter-spacing: -0.1pt">STATEMENTS</FONT></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.3pt">This press
release contains certain forward-looking statements, including those within the meaning </FONT><FONT STYLE="letter-spacing: -0.1pt">of
the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not </FONT><FONT STYLE="letter-spacing: -0.3pt">limited
to statements about the clinical performance of GENFIT&rsquo;s NASH diagnostics technology. The </FONT><FONT STYLE="letter-spacing: -0.2pt">use
of certain words, including &ldquo;believe&rdquo;, &ldquo;potential,&rdquo; &ldquo;expect&rdquo;, &ldquo;target&rdquo;, &ldquo;may&rdquo;
and &ldquo;will&rdquo; and similar </FONT><FONT STYLE="letter-spacing: -0.1pt">expressions, is intended to identify forward-looking statements.
Although the Company believes </FONT>its expectations are based on the current expectations and reasonable assumptions of the <FONT STYLE="letter-spacing: -0.1pt">Company&rsquo;s
management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual
results to differ materially from those </FONT>expressed in, or implied or projected by, the forward-looking statements. These risks
and uncertainties include, among other things, the uncertainties inherent in research and <FONT STYLE="letter-spacing: -0.3pt">development,
including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials,
review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential
commercial success of elafibranor if approved, exchange rate fluctuations, our continued ability to raise capital </FONT>to fund our
development, as well as those risks and uncertainties discussed or identified in the Company&rsquo;s public filings with the AMF, including
those listed in Chapter 2 &ldquo;Main Risks and <FONT STYLE="letter-spacing: -0.3pt">Uncertainties&rdquo; of the Company&rsquo;s 2022
Universal Registration Document filed with the AMF on April 18, 2023, which is available on the Company&rsquo;s website (www.genfit.com)
and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange </FONT><FONT STYLE="letter-spacing: -0.2pt">Commission
(&ldquo;SEC&rdquo;) including the Company&rsquo;s 2022 Annual Report on Form 20-F filed with the SEC </FONT><FONT STYLE="letter-spacing: -0.3pt">on
April 18, 2023 and subsequent filings and reports filed with the AMF or SEC, including the Half- </FONT><FONT STYLE="letter-spacing: -0.1pt">Year
Business and Financial Report at June 30, 2023 or otherwise made public, by the Company.</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><FONT STYLE="letter-spacing: -0.1pt"><B>CONTACT</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>GENFIT</B> | <FONT STYLE="letter-spacing: -0.1pt">Investors</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.3pt">Tel: +33 3
2016 4000 | investors@genfit.com</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.4pt"><B>GENFIT</B> | Press relations</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.2pt">Stephanie Boyer | Tel: +333 2016
4000 | stephanie.boyer@genfit.com</FONT></P>
<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.2pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.2pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.2pt">&nbsp;</FONT></P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B>&nbsp;</B></P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 4pt solid; width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 29px; width: 700px"></TD>
  <TD STYLE="border-bottom: Black 4pt solid; text-align: right; width: 50%">4</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ R0,@ P$1  (1 0,1 ?_$ ,$   $% 0$!
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M:8=3(HH!#0##0 U]*1H#JK&IR>"M+O3E%B4BJE2,FF#P: 6@$O0'4 AH!BJ
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MK:*SJ:P#D9R_6M*J)<1@DB_97/O&VJP0C:;WTKFNCIUV&2\.PUCMJWUV%3(
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M?PO(U2J_=1W%A897$0\=BH#S3I7.DI*GV_LI3W4#"/#Y!)0/E3^]:4+;7/$
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MJ&0H:5R=[L[%[BX=R-*SVV:ZZ-/%A) 2+5A;AM-%BQ$3NU&E3W9.ZM+BH3(
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ME^HDQR9_QGC&<=Y9:^1\@ ;[D^9>RW.FE</-IQS'9<O4\??EN>^8>>>@8_\
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MX)F7QCZA82&1N;W?G)TI8:8B'GL1)Q@#"5"1%.J)37PK'M'93PSV5>.BO2I
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C&NB.?8?NJD$-(!.=M*KB$]451K52I,:Z5<14M'2K0?3)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B SH# 2(  A$! Q$!_\0
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MOQ%JFMP2W#7.I;/.1V4HNT8&T  C\2:G\26LU[X7U6UMHS)/-:2QQH#]YBA
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M&<Y/K1H>B6V@:>UG:O*\;323$RD$Y=BQZ <9-"VU_K7_ "!^7]:?YFE1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
